SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin advances on plans of entering into partnership with Acceliant

26 Feb 2015 Evaluate

Lupin is currently trading at Rs. 1684.00, up by 17.90 points or 1.07 % from its previous closing of Rs. 1666.10 on the BSE.

The scrip opened at Rs. 1668.85 and has touched a high and low of Rs. 1700.00 and Rs. 1648.85 respectively. So far 136109 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1705.60 on 19-Feb-2015 and a 52 week low of Rs. 903.95 on 27-May-2014.

Last one week high and low of the scrip stood at Rs. 1705.60 and Rs. 1604.40 respectively. The current market cap of the company is Rs. 75627.25 crore.

The promoters holding in the company stood at 46.66 % while Institutions and Non-Institutions held 42.51 % and 10.83 % respectively.

Pharma major, Lupin has entered into a partnership with Acceliant, a global technology provider of advanced clinical trial data management solutions. Under this partnership, Lupin would leverage Acceliant's clinical trial platform for its clinical research and trials across Lupin Research programs.

Acceliant platforms ensure smooth execution of clinical data management activities such as database design, UAT and various report formats for business intelligence. It gives a client partner like Lupin a collaborative environment that brings global research teams to work within a single shared environment. 

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.

Lupin Share Price

2343.40 -7.55 (-0.32%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×